Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01236391 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
A Phase 2 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT01236391 is a Phase 2 study that has completed, run by Pharmacyclics. The registered enrollment target is 115 participants.
The verdict
NCT01236391, a Phase 2 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.
Interventions
- DRUG PCI-32765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01236391
The ClinicalTrials.gov registry entry for NCT01236391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCI-32765 is the first listed.
NCT01236391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01236391 about?
NCT01236391 is a clinical study titled "Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)". The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.
What is the current status of trial NCT01236391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2011-02. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01236391?
The interventions under investigation include: PCI-32765 (DRUG).
Who is sponsoring clinical trial NCT01236391?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.